Transfusion Reaction Guideline CA4029 v3
To ensure identification and appropriate management of reactions to blood and blood products. To ensure appropriate senior advice is sought when required particularly for the management of serious or very rare transfusion-associated adverse events.
To ensure all blood / blood product serious incidents are reported to the blood bank. Blood bank will subsequently report incidents to the SABRE Serious Adverse Blood Reactions and Events scheme of the MHRA and national Serious Hazards of Transfusion SHOT scheme if necessary
Clinical GuidelinesThis guideline has been approved by the Trust's Clinical Guidelines Assessment Panel as an aid to the diagnosis and management of relevant patients and clinical circumstances. Not every patient or situation fits neatly into a standard guideline scenario and the guideline must be interpreted and applied in practice in the light of prevailing clinical circumstances, the diagnostic and treatment options available and the professional judgement, knowledge and expertise of relevant clinicians. It is advised that the rationale for any departure from relevant guidance should be documented in the patient's case notes.
The Trust's guidelines are made publicly available as part of the collective endeavour to continuously improve the quality of healthcare through sharing medical experience and knowledge. The Trust accepts no responsibility for any misunderstanding or misapplication of this document.